Einstein MH, et al. - Researchers investigated the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA. HIV+ women with cervical cancer on antiretroviral therapy (ART) tolerated concomitant chemoradiotherapy and in majority, completed all prescribed cycles of radiosensitizing chemotherapy at standard dose. Furthermore, these women displayed comparable 1 year PFS to their HIV-negative counterparts. In this patient population, hematologic toxicities from this standard dosing were frequently self-limiting and manageable.